Khera, Amit V.
Kathiresan, Sekar
Article History
First Online: 13 March 2017
Competing interests
: A.V.K. has received consulting fees from Amarin Pharmaceuticals and Merck & Co. S.K. has received grant support from Bayer Healthcare and Amarin, equity in San Therapeutics, and Catabasis, and received personal fees for scientific advisory board participation for Bayer Healthcare, Catabasis, Regeneron Genetics Center, Merck, Celera, Genomics PLC, Novartis, Sanofi, AstraZeneca, Alnylam, Eli Lilly & Company, Leerink Partners, Noble Insights and Ionis Pharmaceuticals.